Download - Slide Share Portfolio
Institutional Specialty
Many Teams One Destination
Ready Set Success
Institutional Specialty
Ready Set Success
POA One 2008
Many Teams One Destination
POA One 2008
the proof is lifeFocused on the best clinical picture
ion H E A L T H C A R E
2
Concept#1 - ION/atom
I N S P I R A T I O N G R O W S
© 2001 The GlaxoSmithKline Group of CompaniesCAV/CAV/000009 All rights reserved.Printed in USA. October 2001.
PROGRESSRISES FROM A SINGLE VISION…
To support and nurture
the discovery and
distribution of knowledge
in the cardiovascular
sciences on a global basis—
by uniting scientific
endeavor, education
and creativity.
Lifesaving Science. It’s more than our job....It’s our mission.™
A N N O U N C I N GThe GlaxoSmithKline Research & Education
Foundation for Cardiovascular Disease
job....It’s our mission.™
THE GENOMICS EDUCATIONAL WORKSHOP
The Genomics Educational Workshop will provide participants
with up-to-date techniques to research approaches related to evolving
technologies in cardiology. The workshop, to be held in Philadelphia
in June 2002, is offered free of charge to members of the medical
community. Attendees will assume responsibility for their own travel
and lodging expenses. The Foundation will sponsor the travel and
hotel costs for 20 young investigators (fellows or junior faculty)
nominated by their mentors and selected on a merit basis by an
independent panel of Foundation Advisory Board members.
More information is available online at www.cvfoundation.org
Lifesaving Science. It’s more than our job....It’s our mission.™
I O N G R O W S
Developed for efficacy, designed for safety
Favorable composition of PLA provides
long-lasting results
• Microparticles are gradually broken down
and eliminated by normal metabolic pathways
• Slow resorption due to high molecular weight
and crystalline structure
New-Fill®—stable reconstitution for effective administration
• Held within a well-tested emulsifying
and thickening agent
• Injected deep intradermally or
subcutaneously through
a 26 G needle1
• Requires no skin test2
ReshapeRestore
Renew
T O R E ~ R E N E W ~ R E S H A P E ~ R E S T O R E ~ R E N E W
Hycamtin is contraindicated in patients with a history of hypersensitivity to topotecan or to any of its ingredients. Hycamtin should not be used in patients who are pregnant,breast-feeding or those with severe bone marrow depression. The most common serious adverse event is myelosuppression.
Please see following page for brief summary of prescribing information, includingwarnings, precautions and adverse events.
In the treatment of
relapsed ovarian and relapsed small cell lung cancer*…
*Hycamtin is indicated for the treatment of metastatic carcinoma of the ovary after failureof initial or subsequent chemotherapy, and for small cell lung cancer sensitive diseaseafter failure of first-line chemotherapy. In clinical studies submitted to support approval,sensitive disease was defined as disease responding to chemotherapy but subsequentlyprogressing ≥60 days (in the phase 3 study) or ≥90 days (in phase 2 studies) afterchemotherapy. †Hycamtin, as a single agent, is the most frequently prescribed second-lineagent for ovarian and small cell lung cancer (Tandem Cancer Audit, MAT 6/01).
A first choicefor a
second chance†
9nine
nine
sevennine
oneonezero7 00